{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:56:23Z","timestamp":1788666983133,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hainan Province","doi-asserted-by":"publisher","award":["824RC500"],"award-info":[{"award-number":["824RC500"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M712153"],"award-info":[{"award-number":["2022M712153"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22367007"],"award-info":[{"award-number":["22367007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304384"],"award-info":[{"award-number":["82304384"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bioorg.2025.108245","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T01:29:26Z","timestamp":1738805366000},"page":"108245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Development of novel rivastigmine derivatives as selective BuChE inhibitors for the treatment of AD"],"prefix":"10.1016","volume":"157","author":[{"given":"Yuting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghuai","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108245_b0005","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2025.108245_b0010","unstructured":"L. Simon, B. Chlo\u00e9, W. Wendy, World Alzheimer Report 2023: Reducing dementia risk: never too early, never too late, Alzheimer\u2019s Dis. Int., https:\/\/www.alzint.org\/u\/World-Alzheimer-Report-2023."},{"key":"10.1016\/j.bioorg.2025.108245_b0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer's disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.108245_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114464","article-title":"Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress","volume":"238","author":"Sang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108245_b0025","article-title":"Alzheimer's disease drug development pipeline: 2024","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimers Dement. (N Y)."},{"key":"10.1016\/j.bioorg.2025.108245_b0030","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/molecules27061816","article-title":"Role of cholinergic signaling in Alzheimer's disease","volume":"27","author":"Chen","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108245_b0035","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer's disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.bioorg.2025.108245_b0040","doi-asserted-by":"crossref","unstructured":"S. Xing, Q. Li, B. Xiong, Y. Chen, F. Feng, W. Liu, H. Sun, Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism, Med. Res. Rev. 41 (2021) 858-901, https:\/\/doi.org\/10.1002\/med.21745.","DOI":"10.1002\/med.21745"},{"key":"10.1016\/j.bioorg.2025.108245_b0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrn1035","article-title":"Neurobiology of butyrylcholinesterase","volume":"4","author":"Darvesh","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bioorg.2025.108245_b0050","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.neuroscience.2015.04.039","article-title":"Butyrylcholinesterase-knockout reduces brain deposition of fibrillar \u03b2-amyloid in an Alzheimer mouse model","volume":"298","author":"Reid","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.bioorg.2025.108245_b0055","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cca.2006.11.005","article-title":"A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India","volume":"378","author":"Manoharan","year":"2007","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bioorg.2025.108245_b0060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bbr.2015.08.026","article-title":"Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse","volume":"296","author":"Maurice","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bioorg.2025.108245_b0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1586\/14737175.5.5.563","article-title":"Rivastigmine for Alzheimer's disease","volume":"5","author":"Desai","year":"2005","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.bioorg.2025.108245_b0070","doi-asserted-by":"crossref","unstructured":"S.G.D. Santo, F. Prinelli, F. Adorni, C. Caltagirone, M. Musicco, A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease, J. Alzheimers Dis. 35 (2013) 349-361, https:\/\/doi.org\/10.3233\/JAD-122140.","DOI":"10.3233\/JAD-122140"},{"key":"10.1016\/j.bioorg.2025.108245_b0075","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/14656566.2.4.653","article-title":"Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders","volume":"2","author":"Desai","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.108245_b0080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3233\/JAD-132690","article-title":"Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"41","author":"Tan","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bioorg.2025.108245_b0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/gps.1402","article-title":"A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease","volume":"21","author":"Takeda","year":"2006","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.bioorg.2025.108245_b0090","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejmech.2019.07.021","article-title":"Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease","volume":"180","author":"Sang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108245_b0095","doi-asserted-by":"crossref","unstructured":"Z. Liu, X. Li, M. Huang, Z. Su, Q. Zhang, Y. Li, Y. Zhou, L. Yu, W. Liu, Z. Sang, Development of novel fluoro-substituted rivastigmine derivatives as selective AChE inhibitors for the treatment of AD, Med. Chem. Res. 33 (2024) 1-10, https:\/\/doi.org\/10.1007\/s00044-024-03250-y.","DOI":"10.1007\/s00044-024-03250-y"},{"key":"10.1016\/j.bioorg.2025.108245_b0100","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmech.2017.10.006","article-title":"Nature-based molecules combined with rivastigmine: a symbiotic approach for the synthesis of new agents against Alzheimer's disease","volume":"141","author":"Nesi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108245_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112265","article-title":"Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease","volume":"194","author":"Sang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108245_b0110","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.2174\/0113895575258033231024073521","article-title":"In silico pharmacokinetics, molecular docking and molecular dynamics simulation studies of nucleoside analogs for drug discovery- a mini review","volume":"24","author":"Kawsar","year":"2024","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108245_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111958","article-title":"Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease","volume":"187","author":"Sang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108245_b0120","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejmech.2015.02.063","article-title":"Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease","volume":"94","author":"Sang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108245_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115253","article-title":"Development of the \u201chidden\u201d multi-target-directed ligands by AChE\/BuChE for the treatment of Alzheimer's disease","volume":"251","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108245_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104879","article-title":"Design, synthesis and evaluation of cinnamic acid hybrids as multi-target-directed agents for the treatment of Alzheimer's disease","volume":"112","author":"Wang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108245_b0135","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41573-021-00210-8","article-title":"Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials","volume":"20","author":"Patton","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108245_b0140","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2169682","article-title":"Design, synthesis and evaluation of quinoline-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease","volume":"38","author":"Chen","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T21:38:34Z","timestamp":1763847514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":28,"alternative-id":["S0045206825001257"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108245","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of novel rivastigmine derivatives as selective BuChE inhibitors for the treatment of AD","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108245"}}